FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023162983> ?p ?o ?g. }

• W2023162983 endingPage "108" @default.
• W2023162983 startingPage "102" @default.
• W2023162983 abstract "No AccessJournal of UrologyAdult Urology1 Jul 2013A 2-Stage Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Associated with Development of Urinary Symptoms After Radiotherapy for Prostate Cancer Sarah L. Kerns, Nelson N. Stone, Richard G. Stock, Lynda Rath, Harry Ostrer, and Barry S. Rosenstein Sarah L. KernsSarah L. Kerns Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York Departments of Pathology and Genetics, Albert Einstein College of Medicine, New York, New York More articles by this author , Nelson N. StoneNelson N. Stone Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York Department of Urology, Mount Sinai School of Medicine, New York, New York Financial interest and/or other relationship with Myriad Genetics, Amgen, DCMI and PCEC. More articles by this author , Richard G. StockRichard G. Stock Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York Financial interest and/or other relationship with Bard. More articles by this author , Lynda RathLynda Rath Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York More articles by this author , Harry OstrerHarry Ostrer Departments of Pathology and Genetics, Albert Einstein College of Medicine, New York, New York Equal study contribution. More articles by this author , and Barry S. RosensteinBarry S. Rosenstein Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York Department of Dermatology and Preventive Medicine, Mount Sinai School of Medicine, New York, New York Department of Radiation Oncology, New York University School of Medicine, New York, New York Equal study contribution. More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.01.096AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We identified single nucleotide polymorphisms associated with change in the AUA Symptom Score after radiotherapy for prostate cancer. Materials and Methods: A total of 723 patients treated with brachytherapy with or without external beam radiation therapy were assessed at baseline and annually after radiotherapy using the AUA Symptom Score. A 2-stage genome-wide association study was performed with the primary end point of change in AUA Symptom Score from baseline at each of 4 followup periods. Single nucleotide polymorphism associations were assessed using multivariable linear regression adjusting for pre-radiotherapy AUA Symptom Score severity category and clinical variables. Fisher's trend method was used to calculate combined p values from the discovery and replication cohorts. Results: A region on chromosome 9p21.2 containing 8 single nucleotide polymorphisms showed the strongest association with change in AUA Symptom Score (combined p values 8.8×10−6 to 6.5×10−7 at 2 to 3 years after radiotherapy). These single nucleotide polymorphisms form a haplotype block that encompasses the inflammation signaling gene IFNK. These single nucleotide polymorphisms were independently associated with change in AUA Symptom Score after adjusting for clinical predictors including smoking history, hypertension, α-blocker use and pre-radiotherapy AUA Symptom Score. An additional 24 single nucleotide polymorphisms showed moderate significance for association with change in AUA Symptom Score. Several of these single nucleotide polymorphisms were more strongly associated with change in specific AUA Symptom Score items, including rs13035033 in the MYO3B gene, which was associated with straining (beta coefficient 0.9, 95% CI 0.6–1.2, p = 5.0×10−9). Conclusions: If validated, these single nucleotide polymorphisms could provide insight into the biology underlying urinary symptoms following radiotherapy and could lead to development of an assay to identify patients at risk for experiencing these effects. References 1 : Severe genitourinary toxicity following radiation therapy for prostate cancer–how long does it last?. J Urol2013; 189: 116. Link, Google Scholar 2 : The impact of acute urinary morbidity on late urinary function after permanent prostate brachytherapy. Brachytherapy2007; 6: 258. Google Scholar 3 : Long-term urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys2003; 56: 454. Google Scholar 4 : Factors influencing urinary symptoms 10 years after permanent prostate seed implantation. J Urol2012; 187: 117. Link, Google Scholar 5 : Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res2006; 12: 2545. Google Scholar 6 : Sequence variant discovery in DNA repair genes from radiosensitive and radiotolerant prostate brachytherapy patients. Clin Cancer Res2009; 15: 5008. Google Scholar 7 : Influence of multiple genetic polymorphisms on genitourinary morbidity after carbon ion radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys2008; 72: 808. Google Scholar 8 : Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys2006; 64: 527. Google Scholar 9 : Prostate brachytherapy: treatment strategies. J Urol1999; 162: 421. Link, Google Scholar 10 : The American Urological Association symptom index for benign prostatic hyperplasia: The Measurement Committee of the American Urological Association. J Urol1992; 148: 1549. Abstract, Google Scholar 11 : Screening breast cancer patients for ATM mutations and polymorphisms by using denaturing high-performance liquid chromatography. Environ Mol Mutagen2001; 38: 200. Google Scholar 12 : PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet2007; 81: 559. Google Scholar 13 : The International HapMap Project. Nature2003; 426: 789. Google Scholar 14 R: A language and environment for statistical computing, version 2.13.1. : 2011. Vienna, Austria. Google Scholar 15 : Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics2005; 21: 263. Google Scholar 16 : Myosin motor function: the ins and outs of actin-based membrane protrusions. Cell Mol Life Sci2010; 67: 1239. Google Scholar 17 : Molecular characterization of human homologs of yeast MOB1. Int J Cancer2010; 126: 2079. Google Scholar 18 : Regulatory effect of IFN-kappa, a novel type I IFN, on cytokine production by cells of the innate immune system. J Immunol2002; 169: 4822. Google Scholar 19 : Chronic oxidative stress and radiation-induced late normal tissue injury: a review. Int J Radiat Biol2004; 80: 251. Google Scholar 20 : Migration of skin dendritic cells in response to ionizing radiation exposure. Radiat Res2009; 171: 687. Google Scholar 21 : Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys2003; 56: 1085. Google Scholar © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited bySteers W (2018) This Month in Adult UrologyJournal of Urology, VOL. 190, NO. 1, (1-2), Online publication date: 1-Jul-2013. Volume 190Issue 1July 2013Page: 102-108Supplementary Materials Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.Keywordsgenome-wide association studyprostatic neoplasmsmorbidityradiotherapyMetricsAuthor Information Sarah L. Kerns Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York Departments of Pathology and Genetics, Albert Einstein College of Medicine, New York, New York More articles by this author Nelson N. Stone Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York Department of Urology, Mount Sinai School of Medicine, New York, New York Financial interest and/or other relationship with Myriad Genetics, Amgen, DCMI and PCEC. More articles by this author Richard G. Stock Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York Financial interest and/or other relationship with Bard. More articles by this author Lynda Rath Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York More articles by this author Harry Ostrer Departments of Pathology and Genetics, Albert Einstein College of Medicine, New York, New York Equal study contribution. More articles by this author Barry S. Rosenstein Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York Department of Dermatology and Preventive Medicine, Mount Sinai School of Medicine, New York, New York Department of Radiation Oncology, New York University School of Medicine, New York, New York Equal study contribution. More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2023162983 created "2016-06-24" @default.
• W2023162983 creator A5008857530 @default.
• W2023162983 creator A5011373314 @default.
• W2023162983 creator A5012386908 @default.
• W2023162983 creator A5033261943 @default.
• W2023162983 creator A5043561947 @default.
• W2023162983 creator A5090040622 @default.
• W2023162983 date "2013-07-01" @default.
• W2023162983 modified "2023-09-27" @default.
• W2023162983 title "A 2-Stage Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Associated with Development of Urinary Symptoms After Radiotherapy for Prostate Cancer" @default.
• W2023162983 cites W1996695354 @default.
• W2023162983 cites W2003425662 @default.
• W2023162983 cites W2006600752 @default.
• W2023162983 cites W2046581576 @default.
• W2023162983 cites W2058401000 @default.
• W2023162983 cites W2066578638 @default.
• W2023162983 cites W2071538779 @default.
• W2023162983 cites W2072222375 @default.
• W2023162983 cites W2086620284 @default.
• W2023162983 cites W2102550616 @default.
• W2023162983 cites W2111382211 @default.
• W2023162983 cites W2114221591 @default.
• W2023162983 cites W2160069798 @default.
• W2023162983 cites W2161633633 @default.
• W2023162983 cites W2162530578 @default.
• W2023162983 cites W2165601614 @default.
• W2023162983 cites W2166522554 @default.
• W2023162983 cites W2169594765 @default.
• W2023162983 cites W2993539218 @default.
• W2023162983 doi "https://doi.org/10.1016/j.juro.2013.01.096" @default.
• W2023162983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23376709" @default.
• W2023162983 hasPublicationYear "2013" @default.
• W2023162983 type Work @default.
• W2023162983 sameAs 2023162983 @default.
• W2023162983 citedByCount "51" @default.
• W2023162983 countsByYear W20231629832013 @default.
• W2023162983 countsByYear W20231629832014 @default.
• W2023162983 countsByYear W20231629832015 @default.
• W2023162983 countsByYear W20231629832016 @default.
• W2023162983 countsByYear W20231629832017 @default.
• W2023162983 countsByYear W20231629832018 @default.
• W2023162983 countsByYear W20231629832019 @default.
• W2023162983 countsByYear W20231629832020 @default.
• W2023162983 countsByYear W20231629832021 @default.
• W2023162983 countsByYear W20231629832023 @default.
• W2023162983 crossrefType "journal-article" @default.
• W2023162983 hasAuthorship W2023162983A5008857530 @default.
• W2023162983 hasAuthorship W2023162983A5011373314 @default.
• W2023162983 hasAuthorship W2023162983A5012386908 @default.
• W2023162983 hasAuthorship W2023162983A5033261943 @default.
• W2023162983 hasAuthorship W2023162983A5043561947 @default.
• W2023162983 hasAuthorship W2023162983A5090040622 @default.
• W2023162983 hasConcept C104317684 @default.
• W2023162983 hasConcept C121608353 @default.
• W2023162983 hasConcept C126322002 @default.
• W2023162983 hasConcept C135763542 @default.
• W2023162983 hasConcept C143998085 @default.
• W2023162983 hasConcept C146357865 @default.
• W2023162983 hasConcept C151730666 @default.
• W2023162983 hasConcept C153209595 @default.
• W2023162983 hasConcept C2776235491 @default.
• W2023162983 hasConcept C2780192828 @default.
• W2023162983 hasConcept C509974204 @default.
• W2023162983 hasConcept C54355233 @default.
• W2023162983 hasConcept C71924100 @default.
• W2023162983 hasConcept C77411442 @default.
• W2023162983 hasConcept C86803240 @default.
• W2023162983 hasConceptScore W2023162983C104317684 @default.
• W2023162983 hasConceptScore W2023162983C121608353 @default.
• W2023162983 hasConceptScore W2023162983C126322002 @default.
• W2023162983 hasConceptScore W2023162983C135763542 @default.
• W2023162983 hasConceptScore W2023162983C143998085 @default.
• W2023162983 hasConceptScore W2023162983C146357865 @default.
• W2023162983 hasConceptScore W2023162983C151730666 @default.
• W2023162983 hasConceptScore W2023162983C153209595 @default.
• W2023162983 hasConceptScore W2023162983C2776235491 @default.
• W2023162983 hasConceptScore W2023162983C2780192828 @default.
• W2023162983 hasConceptScore W2023162983C509974204 @default.
• W2023162983 hasConceptScore W2023162983C54355233 @default.
• W2023162983 hasConceptScore W2023162983C71924100 @default.
• W2023162983 hasConceptScore W2023162983C77411442 @default.
• W2023162983 hasConceptScore W2023162983C86803240 @default.
• W2023162983 hasIssue "1" @default.
• W2023162983 hasLocation W20231629831 @default.
• W2023162983 hasLocation W20231629832 @default.
• W2023162983 hasOpenAccess W2023162983 @default.
• W2023162983 hasPrimaryLocation W20231629831 @default.
• W2023162983 hasRelatedWork W1980245127 @default.
• W2023162983 hasRelatedWork W2088520467 @default.
• W2023162983 hasRelatedWork W2356105190 @default.
• W2023162983 hasRelatedWork W2362655045 @default.
• W2023162983 hasRelatedWork W2380330452 @default.
• W2023162983 hasRelatedWork W2384708512 @default.
• W2023162983 hasRelatedWork W2400504790 @default.
• W2023162983 hasRelatedWork W2407337938 @default.
• W2023162983 hasRelatedWork W2997819842 @default.
• W2023162983 hasRelatedWork W4288392727 @default.

• next